AMSBIO has added a new range of GCaMP calcium indicators (jGCaMP7b, jGCaMP7c, jGCaMP7f, jGCaMP7s) to their portfolio of ready-to-use adeno-associated virus (AAV) biosensor products. These viruses encoded biosensors are supplied ready for use for neural activity studies in vivo.
While One Nucleus CEO Tony Jones attended the Future of Swedish & Danish Life Science 2019 at Medicon Village last week, Marks & Clerk had Norway covered by co-hosting and co-sponsoring the UT Conference in London. Simon Portman of Marks & Clerk Law gave a contracts training seminar for Norwegian tech companies and Matt Pinney of Marks & Clerk brought them up to speed on the patentability of AI.
Medicines Discovery Catapult integrates Alderley Park’s imaging services and expertise, further enhancing preclinical imaging capabilities
Today [9 April 2019], Medicines Discovery Catapult has agreed with Alderley Park Ltd to integrate Alderley Park’s imaging services and expertise into their pre-clinical imaging capability, further enhancing their offering to UK SMEs.
LabKey, a US-based custom informatics solution provider, offering a freely-accessible, enterprise-quality, open source software platform to help research organisations solve their research data challenges.
In February 2016, LabKey opened its UK office, appointing Dr Jason Leadley, as its Director of European Operations. Relying heavily on engagements driven by the download and use of its open source, Community Edition of its core software platform, LabKey Server.
Kadans enters the UK life science market by acquiring from Imperial College ThinkSpace the B900 building located on the Babraham Research Campus (“BRC”) in Cambridge, adding to its Pan-European science park portfolio. The fully let property accommodates two companies (Abzena and Bicycle Therapeutics) active in the field of cancer and immunology therapeutics, forming a welcome addition to Kadans existing science partner network including tenants such as Genmab, Merus and MDxHealth.
Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced the appointment of Simon Sturge as its new CEO, effective May 1, 2019. Simon succeeds David Chiswell, who remains a scientific adviser to the Company.
Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Cambridge, UK, 03 April 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today the formation of Cellular Highways Ltd. The new spin-out has been founded to commercialise TTP’s proprietary Vortex-Actuated Cell Sorting (VACS) technology, and fast-track development of a first commercial product, Highway 1™. TTP has invested £1.7m ($2.2m) in the spin-out, in addition to over £2m development funding to date.
Building on the success of 2018, LabKey will be holding two User Events in Europe in June 2019.
4th and 5th June: Basel Switzerland
6th June: London
The user events are designed to provide a fun and relaxed forum to learn more about what LabKey is and how we help over 500 research institutions around the world to eliminate and address their research data management challenges.
Lonza is to set up a virtual tenancy at Stevenage Bioscience Catalyst (SBC). Through this collaboration, Lonza’s scientific experts will establish a regular presence at SBC working with the Business Development team, joining a vibrant community for biotech growth and development.